DOCSLIB.ORG

Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C - Janssen Obtains Exclusive Rights in Europe and Other Regions - NEW BRUNSWICK, N.J., June 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) announced today that Janssen Pharmaceutica N.V., a Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to develop and commercialize Vertex's investigational hepatitis C virus (HCV) protease inhibitor, VX-950. Under the agreement, Janssen will have exclusive rights in Europe, South America, the Middle East, Africa and Australia. Vertex will retain exclusive commercial rights to VX-950 in North America. Tibotec Pharmaceuticals, Ltd., another Johnson & Johnson company, will lead the development and commercialization of VX-950 for Janssen. Terms of the Agreement Terms of the transaction include a before-tax upfront payment of $165 million, which will be expensed in the second quarter. In addition, there will be additional payments contingent upon successful development, approval and launch of VX-950 in the regions where Janssen has commercial rights and reimbursement of certain drug development costs. The agreement also includes a royalty on product sales in Europe, South America, the Middle East, Africa and Australia. The Company anticipates that the $165 million payment will largely be offset by other non-recurring gains recognized over the balance of the year. Therefore, this transaction is not expected to impact full year guidance. About VX-950 VX-950 is an investigational oral inhibitor of hepatitis C virus protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents that specifically targets HCV. In clinical studies to date, researchers have observed rapid and dramatic antiviral activity with VX- 950 and no patients have discontinued treatment and no serious adverse events have been reported. About Hepatitis C Hepatitis C is a liver disease caused by the hepatitis C virus, which is found in the blood of people with the disease. HCV, a serious public health concern affecting 170 million people worldwide, is spread through direct contact with the blood of infected people. Though many people with hepatitis C may not experience symptoms, others may have symptoms such as jaundice, abdominal pain, fatigue and fever. Hepatitis C significantly increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. The burden of liver disease associated with HCV infection is increasing, and current therapies only provide sustained benefit in about 50% of patients with genotype 1 HCV, the most common strain of the virus. Specifically targeted antiviral therapies for HCV in clinical development may have the potential to increase the proportion of patients in who the virus can be eradicated. About Johnson & Johnson Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 230 Johnson & Johnson operating companies employ approximately 116,000 men and women in 57 countries and sell products throughout the world. About Janssen Pharmaceutica Within the Johnson & Johnson group, Janssen Pharmaceutica is a worldwide Center of Excellence for integrated R&D, production and general services. In Belgium, the company has sites in Beerse, Geel and Olen, which together account for a workforce of 4,350 persons. With more than 80 drugs to its credit, the company is one of the most innovative in the world and its products are used worldwide in human and animal medicine, and plant and material protection. About Tibotec Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need. (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov or on request from Johnson & Johnson. Johnson & Johnson assumes no obligation to update any forward- looking statements as a result of new information or future events or developments.) SOURCE Johnson & Johnson Investor, Stan Panasewicz, +1-732-524-2524, or Louise Mehrotra, +1-732-524-6491 http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved. News Provided by COMTEX.
Load more

Recommended publications
  • Telaprevir (Incivek)
    © Hepatitis C Online PDF created September 25, 2021, 4:19 pm Telaprevir (Incivek) Discontinued. This treatment has been discontinued. Table of Contents Telaprevir Incivek Summary Drug Summary Adverse Effects Class and Mechanism Manufacturer for United States FDA Status Indications Dosing Clinical Use Cost and Medication Access Resistance Key Drug Interactions Full Prescribing Information Figures Drug Summary Although telaprevir was a promising direct-acting antiviral agent that had impact in the hepatitis C treatment field during 2011 to 2013, it was subsequently replaced by newer direct-acting antiviral agents that were more effective, better tolerated, and more convenient. Based on the dwindling role of telaprevir after newer direct-acting antiviral agents were approved, Vertex pharmaceuticals discontinued the sales and distribution of telaprevir in the United States in October 2014. Telaprevir does have some current importance since persons who previously failed a telaprevir-based regimen may have developed resistant associated variants, which could potentially impact subsequent therapy. Adverse Effects The most significant adverse effects reported in the main registration trials and in post-marketing experience were rash, anorectal complaints, and anemia. When comparing triple therapy of telaprevir, peginterferon, and ribavirin with dual therapy of peginterferon and ribavirin alone significant differences were noted with rash (56% versus 34%), anemia (36% versus 17%), and anorectal complaints that include anorectal discomfort, anal pruritus, and hemorrhoids (29% versus 7%). In most cases, the rash that develops is eczematous or maculopapular in character and mild to moderate in severity; the rash is typically manageable with good skin care and topical emollients or corticosteroids. In some instances, however, telaprevir has caused serious skin Page 1/5 rashes, including Steven's Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN).
    [Show full text]
  • Contract Reduces Scientists' Workload
    MAINTENANCE HPLC set-up with system layout (flat screen). On the left, a Waters Micromass 996 with Photo Diode Array detection. Janssen Pharmaceuticals outsources central management of 17,000 lab instruments COMPREHENSIVE MAINTENANCE contract reduces scientists’ workload Els van den Brink, Images: FOODnote Janssen Pharmaceuticals Beerse, a J&J subsidiary, has Not only has Beerse maintenance been outsourced, but outsourced the maintenance of all its lab equipment. The also equipment from the Janssen-labs in Geel (raw materials production) and Merksem (clinical facility). After eighteen months decision has big advantages; the equipment’s maintenan- and proven success, J&J is rolling this approach out to other ce status is clear, maintenance is more efficient, up-time is European sites. In Belgium, 17,000 lab instruments are centrally increased and costs are lower thanks to economies of scale managed – 14,000 of them in Beerse. Outsourcing doesn’t just with existing suppliers. But above all, outsourcing reduces relieve the lab managers of a task, but also provides them with a the administrative workload for lab managers and analysts. complete overview of their equipment maintenance strategy so they can manage their equipment based on Key Performance 2 LABinsights | December 2017 MAINTENANCE Indicators (KPIs). Scientists can call on a dedicated team Pilot study of qualified engineers onsite who address acute problems The 14,000 instruments in Beerse are housed in 12 buildings. affecting critical equipment. Valued at half a billion euros, this equipment costs 10 million euro a year in maintenance, Van Deun says. Centralizing the KPIs maintenance of so much equipment is a major effort, so it was At Janssen, Senior Manager of Laboratory Services Jan Van done in phases.
    [Show full text]
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • Vertex Pharmaceuticals Global Medical Affairs Pharmd Fellowship Program 2020 Message from Global Medical Affairs Leadership
    Vertex Pharmaceuticals Global Medical Affairs PharmD Fellowship Program 2020 Message from Global Medical Affairs Leadership Dear Candidates, Vertex Pharmaceuticals in collaboration with Northeastern University is privileged to host and expand the PharmD Fellowship Program. We are excited to work with our fellows as integral members of our team and facilitate in-depth exposure to a range of functional areas, offering them the critical opportunity to gain extensive experience in the biopharmaceutical industry. In addition to fostering each individual’s personal and professional growth, the program’s primary goal is to extend the visibility of valuable contributions that a Doctor of Pharmacy can bring to the pharmaceutical industry. At Vertex, our Global Medical Affairs fellows are highly encouraged to take on immersive projects, allowing them to work across departments with leaders in the industry. We advocate for them to partake in truly unique, impactful work that develops their skills, sparks curiosity, and drives the science. Vertex’s open and innovative culture allows the fellows to ask questions, challenge the status quo, and explore their interests across multiple expertise areas. As a pharmacist, I am extremely proud of the establishment of the Vertex PharmD Fellowship program in Global Medical Affairs and excited to welcome our future fellows. Vertex is an ideal place for fellows to start their professional career, and we are dedicated to the development of the next generation of pharmacist leaders in the biopharmaceutical industry. As Vertex continues to grow and evolve into a company in multiple disease areas, I am confident that our fellows will be an essential part of moving the needle to deliver on our commitment to patients.
    [Show full text]
  • Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20
    Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20 RAAP België - Rapport 125 Beheerboerderij Weerstandersstraat, Beerse Archeologienota Archeologisch Vooronderzoek Verslag van de Resultaten Bureauonderzoek – 2017H20 Nazareth 2017 0 Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20 Colofon Opdrachtgever: Agentschap voor Natuur en Bos Titel: Beheerboerderij Weerstandersstraat Beerse Archeologienota Archeologisch Vooronderzoek Bureauonderzoek - 2017H20 Status: Definitief Datum: 20 september 2017 Auteur: Hannes Van Crombrugge Projectcode: 2017H20 Raapproject: BEWE01 Erkend archeoloog: RAAP België (OE/ERK/Archeoloog/2016/00154) Bewaarplaats documentatie: RAAP België, Steenweg Deinze 72, 9810 Nazareth Bevoegd gezag: agentschap Onroerend Erfgoed RAAP België BVBA Steenweg Deinze 72 9810 Nazareth telefoon: 09/311 56 20 - 0498/44 16 99 E-mail: [email protected] © RAAP België bvba, 2017 RAAP België aanvaardt geen aansprakelijkheid voor eventuele schade voortvloeiend uit het gebruik van de resultaten van dit onderzoek of de toepassing van de adviezen. 1 Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20 Inhoudsopgave Inhoudsopgave ........................................................................................................................................ 2 Samenvatting ........................................................................................................................................... 3 1 Verslag van resultaten: bureauonderzoek 2017H20 ......................................................................
    [Show full text]
  • PROVINCIE ANTWERPEN BESTUURLIJK ARRONDISSEMENT ANTWERPEN Pagina 1 Van 48 PROVINCIE ANTWERPEN Datum: 17/08/2017
    PROVINCIE ANTWERPEN Datum: 17/08/2017 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) D tot. C O diagn bijk erk opm V - V V + (V 1bis) C B C M C H CB AW CB AW B CB AW M BEG CAP BESTUURLIJK ARRONDISSEMENT ANTWERPEN VZW Emmaüs DE GROTE ROBIJN Korte Sint-Annastraat 4 2000 Antwerpen 16 23 Telefoon: 03 231 25 75 12-18j 0-18j j-m j-m Fax: E-mail: [email protected] VER Zorgbedrijf Antwerpen CENTRA BIJZONDERE JEUGDZORG ZORGBEDRIJF ANTWERPEN Ballaarstraat 35 53 2018 Antwerpen 25 43 4 3 3 Telefoon: 03 334 44 50 0-18j 0-18j 0-18j j-m j-m j-m Fax: E-mail: [email protected] AFDELINGEN: PROVINCIE ANTWERPEN BESTUURLIJK ARRONDISSEMENT ANTWERPEN Pagina 1 van 48 PROVINCIE ANTWERPEN Datum: 17/08/2017 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) D tot. C O diagn bijk erk opm V - V V + (V 1bis) C B C M C H CB AW CB AW B CB AW M BEG CAP 18 3 DE WENDING 13 0-18j j-m Lamorinièrestraat 236 12-18j j-m 2018 Antwerpen 29 3 PENNSYLVANIA FOUNDATION 13 0-18j j-m Gouverneur Holvoetlaan 28 0-18j j-m 2100 Antwerpen VZW Elegast ELEGAST Belgiëlei 203 20 158 2018 Antwerpen 12 15 6-18j 94 32 6 26 j-m Telefoon: 03 286 75 25 0-12j 0-18j 0-18j 0-18j j-m j-m j-m j-m Fax: E-mail: [email protected] AFDELINGEN: PROVINCIE ANTWERPEN BESTUURLIJK ARRONDISSEMENT ANTWERPEN Pagina 2 van 48 PROVINCIE ANTWERPEN Datum: 17/08/2017 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) D tot.
    [Show full text]
  • Ravels - Tilburg PPEERDRD Ilburg Ravelsravels -- Ttilburg Monumental Statue of Renier N12N12
    Baarle-Hertog/Nassau N 15 Merksplas - i Tourism & UiT Hoogstraten1 Beguinage / Beguinage Museum 2 Taxandria Museum ON RIM IO M T U • A P N W D O I A R L L D H E • L R 3 I A T I ONIO A D RIM M G N T U Castle of E • A N O P • W PA E M D T O I RIMOIN A R L L D H E • L R A IT I A D G N Some statues you should absolutely not miss E O •P M ATRIMOINE the Dukes of Brabant Baarle-Hertog/Nassau N 15 4 Meduceum Renier Snieders (1930) 5 On the Patersplein (Monk’s Centre of cultural life ‘de Warande’ square) you will find the 14 6 City hall / Archives monumental statue of Renier Snieders. The statue was made BaBaarlarle-Hee-Hertog/Nrtog/Nassau ! Breda N119 7 Marketplace / St Peter’s Church as a memorial for this Dutch 13 N KAMPHEIDE doctor and writer. Snieders KAMPHEIDE ZWART WATER ZWART WATER 23 ONIO M IM UN TR D A IA • P L W O R • L L D A I H D E R N IT O A M G E E• IN Merksplas - PATRIMO Tip Hoogstraten DOMBERGHEIDE DOMBERGHEIDE 8 He izide ENGELAND was born in 1812 in Bladel, The ENGELAND National Playing e Heizid Ravels - Tilburg 22 NIEUWE BOSSEN NIEUWE BOSSEN Kas telei DEN DOOLHOF DEN DOOLHOF n dekensweg Vel PPEEERRDDSVVEEN 21 Ko n Have a walk around Turnhout and E MerksplasMeMerksplrksplasas 20 lis abe HoogsHoogsHoogsttratentratenen Steenweg op Merksplas th Netherlands, but later had a le Wouwerstraat i Oosthoven NN124124 wg op St RavelsRavels -- TTilburgilburg umlaan bile N12N12 u 24 J Plamaten19 einstraat f Font ree nend Til- e Begi Koning Albertstraat 22 n N 25 elestr NIO M MOO NOI MUU RI I M N N T R D D 1 A T AI t I • • P A LA • P L W W W W W O O O O R • • R L • L L D L D A I A I H H D E D R E N I R N TI O AT M O GA E M EG I E •EPAT O NNI 18 •PARTIRMIMO ai Beginhof nsstraa Hoveniersstraat aa e Ka Gul K e FIFIFILLILIPPIPKKEEKNENSVNSVISVIJIJVJVVEERER let de brand new signposting w densporenlei aste t Card Museum Ka ieu ndek N el Patersstraat dreef Li rel Oomst Brugstraat at 23 straat tra doctor’s practice in Turnhout.
    [Show full text]
  • Archeologische Begeleiding Verkaveling Beekakkers in Beerse
    ADAK RAPPORT 4 Archeologische begeleiding verkaveling Beekakkers in Beerse S. DELARUELLE & J. VAN DONINCK De Archeologische dienst Antwerpse Kempen is een projectvereniging van de gemeenten Beerse, Oud-Turnhout, Turnhout en Vosselaar met steun van de Vlaamse gemeenschap en de provincie Antwerpen. Colofon Opdrachtgever Hermans BVBA Project Beerse-Beekakkers Projectcode 07004 Vergunning 2007/46/13506 Auteurs Stephan Delaruelle & Jef Van Doninck Kaarten & plannen Stephan Delaruelle (©NGI/GIS Vlaanderen) Foto’s & tekeningen Stephan Delaruelle Omslagontwerp Hanna Maes ISBN / © AdAK , december 2007 Niets uit deze uitgave mag worden verveelvoudigd en/of openbaar gemaakt door middel van druk, fotokopie, microfilm of op welke andere wijze dan ook, zonder voorafgaande schriftelijke toestemming van de Archeologische Dienst Antwerpse Kempen. Beerse-Beekakkers AdAK Samenvatting Op 10 mei 2007 werd door de Archeologische Dienst Antwerpse Kempen (AdAK) in samenwerking Hermans BVBA een archeologische begeleiding van de aanleg van de wegkoffers uitgevoerd binnen de verkaveling Beekakkers aan de Beekakkerstraat te Beerse. Tijdens het onderzoek werd de ontgraving van de centraal gelegen wegkoffer opgevolgd alsook de sanering van de achterliggende gebieden, waarbij in totaal ca. 1500 m2 werd onderzocht. Tijdens het onderzoek werden geen archeologisch relevante sporen vastgesteld. Opmerkelijk was ook dat natuurlijke sporen grotendeels ontbraken. Doordat het plangebied tot voor kort in gebruik was als kwekerij voor buxusplanten, waren in de onaangeroerde bodem groene en oranje verkleuringen af te lezen, die vermoedelijk te maken hebben met de het gebruik van meststoffen en insecticiden. In het bodemprofiel was ook af te lezen dat een groot gedeelte van het terrein was afgegraven en omgezet bij de inrichting van het plantenbedrijf, zoals ook door de eigenaar was aangegeven.
    [Show full text]
  • United States Securities and Exchange Commission Form
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2005 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.) 130 Waverly Street Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (617) 444-6100 Registrant’s telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01. Other Events. On June 17, 2005, Vertex Pharmaceuticals Incorporated and Merck & Co., Inc. issued a joint press release that announced the initiation of an additional Phase I study with VX-680, a small molecule inhibitor of Aurora kinases. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01.
    [Show full text]
  • Bijlagen.Pdf
    Bijlagen Inhoud Bijlage 1: Het hoe en waarom van een ruimtelijk structuurplan..........................................................7 1.1. Het wetgevend kader.........................................................................................................................7 1.1.1. Het decreet van 18 mei 1999 ...........................................................................................................7 1.1.2. Omzendbrief RO 97/02 over het gemeentelijk structuurplanningsproces........................................7 1.2. Aanpak structuurplanning Wuustwezel..........................................................................................8 1.2.1. Planningsmethodiek .........................................................................................................................8 1.2.2. Communicatie en organisatie.........................................................................................................10 Bijlage 2: Verbanden met het Ruimtelijk Structuurplan Vlaanderen (RSV)......................................14 2.1. Deelstructuren in het RSV ..............................................................................................................14 2.2. Buitengebied....................................................................................................................................14 2.2.1. Doelstellingen voor het buitengebied .............................................................................................14 2.2.2. Functies in het buitengebied ..........................................................................................................15
    [Show full text]
  • Provinciaal Ruimtelijk Uitvoeringsplan
    provinciaal ruimtelijk uitvoeringsplan Voorstudie PRUP Retentiezone Laak Beerse Memorie van toelichting inclusief m.e.r.-screening Ruimtelijk planner: Steven Muylaert Dienst Ruimtelijke Planning Dienst Colofon Opdrachtgever: Dienst Ruimtelijke Planning Provincie Antwerpen Koningin Elisabethlei 22, 2000 Antwerpen tel.: 03 240 66 00 fax: 03 240 66 79 [email protected] contactpersoon: Stein Temmerman [email protected] 03/240.56.10 Opdrachthouder: D+A Consult nv Meiboom 26 1500 Halle contactpersoon: Steven Muylaert [email protected] 02/371.02.57 Dossiernummer: <ROPR/08-45> D+A Consult nv Inhoud 1. Inleiding ........................................................................................................................ 5 1.1. Aanleiding van de opdracht ....................................................................................... 5 1.2. Procesverloop .......................................................................................................... 5 2. Algemene situering ......................................................................................................... 6 2.1. Macro ..................................................................................................................... 6 2.2. Meso ...................................................................................................................... 6 2.3. Micro ...................................................................................................................... 7 3. Planningscontext ...........................................................................................................
    [Show full text]
  • Pax Large Cap Fund USD 7/31/2021 Port
    Pax Large Cap Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight Microsoft Corporation 89,240,649.84 6.2 Apple Inc. 56,474,074.80 3.9 Alphabet Inc. Class A 45,168,406.39 3.1 Applied Materials, Inc. 40,802,748.42 2.8 United Parcel Service, Inc. Class B 40,145,031.68 2.8 Amazon.com, Inc. 40,024,252.52 2.8 Procter & Gamble Company 38,175,527.61 2.6 Alphabet Inc. Class C 37,288,542.96 2.6 T-Mobile US, Inc. 36,913,478.16 2.5 CVS Health Corporation 35,823,305.60 2.5 Bristol-Myers Squibb Company 35,683,263.33 2.5 Trane Technologies plc 34,492,144.83 2.4 Voya Financial, Inc. 34,364,677.20 2.4 Fiserv, Inc. 33,109,434.63 2.3 Medtronic Plc 32,631,060.24 2.2 Lowe's Companies, Inc. 32,345,328.78 2.2 JPMorgan Chase & Co. 31,275,786.80 2.2 salesforce.com, inc. 31,164,938.74 2.1 Aptiv PLC 30,049,685.00 2.1 Target Corporation 29,624,476.10 2.0 Becton, Dickinson and Company 29,334,525.00 2.0 Citizens Financial Group, Inc. 28,825,635.20 2.0 Merck & Co., Inc. 28,216,517.16 1.9 BlackRock, Inc. 28,142,268.01 1.9 Vertex Pharmaceuticals Incorporated 26,265,874.00 1.8 Lincoln National Corporation 25,842,318.84 1.8 Sysco Corporation 25,428,711.00 1.8 Equinix, Inc.
    [Show full text]